New Data Confirm That Use of Levemir Can Limit Weight Gain ( COPENHAGEN April 3 2007-Newly publis...)

New Data Confirm That Use of Levemir Can Limit Weight Gain

COPENHAGEN, April 3, 2007-Newly published results in the International Journal of Clinical Practice(1) from the large-scale, observational ‘PREDICTIVE™ study’*, confirm that Levemir® for the majority of people effectively treats diabetes without causing weight gain.(1)

The PREDICTIVE™ study is examining patient outcomes when Levemir® – a long-acting modern insulin – is used in the everyday clinical setting. In the European cohort of PREDICTIVE™, a total of 20,531 people with type 1 and type 2 diabetes from 11 countries were prescribed Levemir® and followed up after 14 weeks. At this time there was not only an improvement in patients’ average blood glucose levels, but also a decrease in their average body weight. This applied to people with type 1 as well as type 2 diabetes.(1)

Professor Russell-Jones, of the Department of Diabetes and Endocrinology, Royal Surrey County Hospital, Surrey, UK, commented that: "Insulin initiation is often associated with considerable weight gain, which is a major problem for people with type 2 diabetes. Studies have shown that even a modest weight reduction can improve the cardiovascular risk profile of these people. The reduced risk of weight gain that Levemir® offers potentially provides people with diabetes an enhanced treatment option."

The risk of weight gain may act as a significant barrier to the initiation of insulin therapy or it may hinder compliance with it.(2,3) This can mean that patients remain in poor blood glucose control, which is associated with an increased risk of diabetic complications. Furthermore, increasing weight gain can in itself lead to health problems such as increasing insulin resistance, high blood pressure and raised cholesterol levels, all of which are also associated with an increased risk of cardiovascular diseases.(2,3)

On the other hand, it has been estab
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
5. New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis
6. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
7. New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients
8. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
9. Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress

Post Your Comments:

( COPENHAGEN April 3 2007-Newly publis...)New Data Confirm That Use of Levemir Can Limit Weight Gain,Health